Skip to main content
    K

    Krystal Biotech Inc (KRYS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $300.88
    +0.63 (+0.21%)

    Market Cap: $9.21B

    Last updated: Nov 06, 2026 at 4:39 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(21/37)
    Avg Surprise
    +9.27%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$2.34
    Range$1.52 - $5.01
    11 analysts
    Revenue Consensus
    $137M
    Range$125M - $157M
    10 analysts
    Last 12 of 38 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$2.34$1.52 - $5.01--11--
    Sep 26
    Reported Nov 2
    		$2.05$1.84$1.49 - $3.04+11.41%Beat10
    0
    1
    30d
    		-22.9%
    Jun 26
    Reported Aug 3
    		$1.79$1.70$1.28 - $3.64+5.29%Beat8
    0
    1
    30d
    		+38.8%
    Mar 26
    Reported May 4
    		$1.83$1.42$1.28 - $1.61+28.87%Beat7
    0
    1
    30d
    		+52.5%
    Dec 25
    Reported Feb 17
    		$1.70$1.58$1.36 - $1.92+7.59%Beat3
    No revisions (30d)
    		+11.1%
    Sep 25
    Reported Nov 3
    		$2.66$1.12$0.99 - $1.24+137.50%Beat4
    1
    0
    30d
    		+192.3%
    Jun 25
    Reported Aug 4
    		$1.29$1.44$1.11 - $2.11-10.42%Miss4
    1
    1
    30d
    		+38.7%
    Mar 25
    Reported May 6
    		$1.20$1.52$1.47 - $1.57-21.05%Miss2
    1
    0
    30d
    		+3900.0%
    Dec 24
    Reported Feb 19
    		$1.53$1.85$1.15 - $3.21-17.39%Miss3
    1
    0
    30d
    		+59.4%
    Sep 24
    Reported Nov 4
    		$0.91$0.90$0.63 - $1.16+1.11%Beat8
    No revisions (30d)
    		+235.8%
    Jun 24
    Reported Aug 5
    		$0.93$0.99$0.78 - $1.37-6.06%Miss6
    1
    1
    30d
    		+174.4%
    Mar 24
    Reported May 6
    		$0.03N/A--80.00%Miss7
    2
    0
    30d
    		+101.7%
    Dec 23
    Reported Feb 26
    		$0.96$-0.25$-0.95 - $-0.01+484.00%Beat8
    0
    1
    30d
    		+176.8%

    Key Metrics

    Valuation
    P/E Ratio40.82EV/EBITDA36.05x
    Price/FCF28.73xFCF Yield3.48%
    Profitability
    Profit Margin47.90%Operating Margin55.90%
    ROE17.50%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio7.89xQuick Ratio7.53x
    Trading Statistics
    Beta0.65Avg Volume323.19K
    52-Week High$382.5452-Week Low$197.13

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$312.54
    SMA 20$317.77
    SMA 50$332.49
    SMA 200$309.01
    EMA 10$310.24
    EMA 20$316.39
    EMA 50$326.07
    EMA 200$303.95

    MACD

    Line: -7.50Signal: -6.07Hist: -1.43

    ADX

    ADX: 18.9+DI: 16.2-DI: 29.1

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down84.0
    PSAR$328.65

    Bollinger Bands

    Upper Band$339.48
    Lower Band$296.06
    %B Position1366%(Upper)
    Band Width0.11

    RSI (14-Day)

    Neutral
    39.9

    Momentum Oscillators

    Stoch %K44.1
    Stoch %D43.5
    Williams %R-62.0
    ROC (10d)-3.4%
    Momentum-10.62
    CCI (20d)-132.2
    MFI (14d)46.2

    Volatility Measures

    ATR (14d)$12.71(4.2%)
    StdDev (20d)10.85
    Hist Vol51.7%(High)

    Volume Flow

    VWAP$301.33
    OBV9.3M
    AD Line5.1M
    CMF (20d)0.017

    Volume Metrics

    Avg Vol (20d)332.1K
    Vol Ratio0.7x
    VWMA (20d)$313.52

    Pivot Points

    R3$324.39
    R2$319.32
    R1$309.78
    Pivot Point$304.71
    S1$295.17
    S2$290.10
    S3$280.56

    Advanced Oscillators

    TSI-16.47
    Ultimate Osc47.8
    KST-61.24

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$127.34M$119.22M$116.36M$107.11M$97.80M$96.04M$88.18M$91.14M$83.84M$70.28M$45.25M$42.14M
    Cost of Revenue$7.56M$6.44M$6.32M$6.59M$4.26M$7.17M$5.03M$4.95M$6.68M$6.01M$2.42M$3.09M
    Gross Profit$119.78M$112.78M$110.03M$100.51M$93.54M$88.88M$83.16M$86.19M$77.16M$64.28M$42.83M$39.05M
    Operating Expenses$48.64M$54.37M$56.34M$56.08M$52.16M$49.48M$46.90M$44.80M$54.69M$55.71M$49.52M$36.02M
    R&D$14.89M$14.52M$15.33M$14.79M$14.59M$14.41M$14.26M$13.53M$13.51M$15.58M$10.96M$11.37M
    SG&A$33.75M$39.85M$41.01M$41.28M$37.58M$35.07M$32.65M$31.27M$28.67M$27.63M$26.06M$24.65M
    Operating Income$71.14M$58.42M$53.69M$44.44M$41.37M$39.40M$36.25M$41.39M$22.47M$8.57M$-6,684,000$3.25M
    Interest Income$9.00M$7.66M$7.75M$6.70M$6.59M$7.38M$7.34M$7.22M$7.30M$7.48M$7.62M$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$80.14M$66.08M$61.44M$51.13M$47.97M$46.77M$43.60M$48.61M$29.77M$16.05M$932,000$10.66M
    Income Tax Expense$17.08M$11.31M$5.51M$-268,000$-31,398,000$8.44M$7.86M$3.13M$2.59M$477,000$0$0
    Net Income$63.07M$54.77M$55.93M$51.40M$79.36M$38.33M$35.73M$45.48M$27.18M$15.57M$932,000$8.69M
    EBITDA$72.83M$59.98M$55.41M$46.06M$42.99M$40.94M$37.89M$42.95M$24.00M$10.59M$-5,075,000$5.00M
    EBIT$71.14M$58.42M$53.69M$44.44M$41.37M$39.40M$36.25M$41.39M$22.47M$8.57M$-6,684,000$3.25M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KRYS

    KRYS Valuation and Fair Value

    P/E
    40.8x
    Forward P/E
    43.9x
    EV/EBITDA
    36.1x
    P/FCF
    28.7x
    P/B
    6.2x
    See GNG's fair value

    KRYS Profitability: Margins, ROIC and FCF

    Gross margin
    94.3%
    Operating margin
    55.9%
    Net margin
    47.9%
    ROE
    17.5%
    FCF margin
    66.0%
    FCF yield
    3.5%

    KRYS Competitors

    CompanyTicker
    Protagonist Therapeutics IncPTGX
    Spyre Therapeutics Inc.SYRE
    Madrigal Pharmaceuticals IncMDGL
    AptarGroup IncATR
    Hinge Health, Inc.HNGE
    HealthEquity IncHQY
    Henry Schein IncHSIC
    TG Therapeutics IncTGTX

    Sector: Healthcare

    KRYS Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    1
    Buy
    10
    Hold
    1
    Sell
    0
    Strong Sell
    0

    KRYS Bull Case vs Bear Case

    Bull case

    • KRYS converts 66.0% of revenue into free cash flow.
    • KRYS has a 47.9% net profit margin.
    • KRYS grew quarterly revenue 30.2% year over year.

    Bear case

    • KRYS trades at 40.8x trailing earnings.

    KRYS Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    17.7%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $2.34

    KRYS Earnings Date

    KRYS reports Feb 15, 2027, after the close. The date is estimated.

    KRYS Earnings Call

    The latest KRYS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    KRYS ETF Holders

    GNG tracks 18 ETFs that hold KRYS. The largest weights:

    1. ERShares Private-Public Crossover ETF (XOVR), 2.15% of the fund
    2. State Street SPDR S&P Biotech ETF (XBI), 1.33% of the fund
    3. Invesco S&P MidCap Momentum ETF (XMMO), 1.27% of the fund
    4. iShares Biotechnology ETF (IBB), 0.58% of the fund
    5. abrdn Healthcare Investors (HQH), 0.43% of the fund
    Open the ETF Stock Exposure tool for KRYS

    See insider activity

    Frequently Asked Questions About KRYS

    When does KRYS report earnings?

    Krystal Biotech Inc (KRYS) is expected to report earnings on Feb 15, 2027.

    Does KRYS pay dividends?

    Krystal Biotech Inc (KRYS) does not currently pay a regular dividend.

    What is KRYS's P/E ratio?

    Krystal Biotech Inc has a price-to-earnings (P/E) ratio of 40.82.

    What is KRYS's market cap?

    Krystal Biotech Inc (KRYS) has a market capitalization of $9.21B with a current stock price of $300.88.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In